CTOs on the Move

Marubeni-Itochu Steel America

www.misteel.com

 
MISA is a metal solutions provider not only to companies worldwide, but also right next door. We offer value-added steel and aluminum solutions to customers in the automotive, construction, appliance, food, medical, and aerospace industries, just to name a few. Whether you`re an automotive manufacturer looking for Supply Chain Management services, an industrial equipment manufacturer requiring quality Metal Processing, or a builder in the construction market needing Residential and Commercial Building Materials, MISA provides innovative solutions for all your needs. At the core of our Philosophy is a commitment to being the best and most innovative metal supply chain supplier, all the ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.misteel.com
  • 655 3rd Ave Ste 700
    New York, NY USA 10017
  • Phone: 212.542.8484

Executives

Name Title Contact Details

Similar Companies

I H C Services

I H C Services, Inc is a New York, NY-based company in the Business Services sector.

Southern Rents

Southern Rents is a Dyersburg, TN-based company in the Business Services sector.

art slave

art slave is a Santa Monica, CA-based company in the Business Services sector.

Vajrasoft

Vajrasoft is a Birmingham, AL-based company in the Business Services sector.

Apellis Pharmaceuticals

Apellis Pharmaceuticals is a global biopharmaceutical company based in Waltham, Massachusetts. The company is focused on developing innovative therapies that target the complement system, a crucial part of the immune system. Apellis aims to create life-changing treatments for various debilitating diseases through its commitment to scientific research and patient care. The company has a diverse pipeline of products, including EMPAVELI, which is approved for treating paroxysmal nocturnal hemoglobinuria and is being investigated for other conditions. SYFOVRE is in development for geographic atrophy, along with a combination therapy involving APL-APL-3007. Apellis is also exploring RNA therapies and gene-edited treatments for multiple therapeutic areas. With a global presence in countries such as the US, Canada, and several European nations, Apellis serves patients and healthcare providers affected by diseases related to the complement system. The company reported approximately $709 million in U.S. net product revenues for the full year 2024, reflecting its strong market position and commitment to advancing its therapeutic offerings.